Oragenics signs LOI to license CardioDialysis from Sigyn Therapeutics for TBI

ORAGENICS INC

LOI grants Oragenics exclusive license for CardioDialysis blood purification tech in TBI and chronic neurodegenerative diseases.
Consideration: 3,250,000 shares of preferred stock convertible 1:1 to common, plus 3% royalty for 6 years post-FDA clearance.
Target closing within 90 days; Sigyn exclusivity during that period; subject to due diligence, board approvals, and NYSE American rules.
Oragenics also advancing ONP-002 (Phase IIa intranasal neurosteroid); combined approach targets TBI inflammation on both sides of BBB.
No FDA-approved pharmacological treatment for concussion/mTBI; 69 million brain injuries occur annually worldwide.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-021627
form_type: 8-K
ticker: OGEN
cik: 0001174940
company_name: ORAGENICS INC
filed_at: 2026-05-07T23:59:59+00:00
discovered_at: 2026-05-14T18:02:32.034490+00:00
generated_at: 2026-05-14T21:24:57.785972+00:00
sec_items: ["8.01", "9.01"]
event_type: m_and_a
sentiment: positive
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-021627
json_url: https://secwatch.observer/filing/0001493152-26-021627.json
markdown_url: https://secwatch.observer/filing/0001493152-26-021627.md
text_url: https://secwatch.observer/filing/0001493152-26-021627.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1174940/000149315226021627/0001493152-26-021627-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1174940/000149315226021627/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-26-021627

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.